NASDAQ:SBTX Silverback Therapeutics (SBTX) Stock Price, News & Analysis $14.32 -0.19 (-1.31%) (As of 09/27/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends Get Silverback Therapeutics alerts: Email Address About Silverback Therapeutics Stock (NASDAQ:SBTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SBTX alerts:Sign Up Key Stats Today's Range$13.83▼$14.9950-Day Range$5.87▼$14.8952-Week Range$2.80▼$8.97Volume615,988 shsAverage Volume337,931 shsMarket Capitalization$516.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSilverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Read More… Don’t wait for FDA approval (Ad)Don’t let Wall Street fool you. AI is not the only hot sector in the market. Biotech is on fire as well.And I’ll tell you all about them in this video. Receive SBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silverback Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SBTX Stock News HeadlinesSilverback Therapeutics (NASDAQ:SBTX) Hits New 12-Month High at $14.23September 27 at 7:42 PM | americanbankingnews.comSilverback Therapeutics (NASDAQ:SBTX) Reaches New 1-Year High at $14.32September 20, 2024 | americanbankingnews.comHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.September 27, 2024 | Monument Traders Alliance (Ad)Silverback Therapeutics (NASDAQ:SBTX) Trading Up 0.8%September 19, 2024 | americanbankingnews.comARS Pharmaceuticals Inc (SPRY)May 11, 2023 | uk.investing.comSPRY ARS Pharmaceuticals, Inc.January 24, 2023 | seekingalpha.comARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After MergerNovember 22, 2022 | 247wallst.comDr. Sarina Tanimoto Discloses Position in SBTX / Silverback TherapeuticsNovember 18, 2022 | nasdaq.comSee More Headlines SBTX Stock Analysis - Frequently Asked Questions How have SBTX shares performed this year? Silverback Therapeutics' stock was trading at $5.48 at the beginning of 2024. Since then, SBTX shares have increased by 161.3% and is now trading at $14.32. View the best growth stocks for 2024 here. How were Silverback Therapeutics' earnings last quarter? Silverback Therapeutics, Inc. (NASDAQ:SBTX) issued its earnings results on Wednesday, November, 10th. The company reported ($0.65) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.65). When did Silverback Therapeutics IPO? Silverback Therapeutics (SBTX) raised $126 million in an initial public offering on Friday, December 4th 2020. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs, SVB Leerink and Stifel acted as the underwriters for the IPO and H.C. Wainwright was co-manager. How do I buy shares of Silverback Therapeutics? Shares of SBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings11/10/2021Today9/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SBTX CUSIPN/A CIK1671858 Webwww.silverbacktx.com Phone206 456 2900FaxN/AEmployees83Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.62% Return on Assets-28.20% Debt Debt-to-Equity RatioN/A Current Ratio67.87 Quick Ratio67.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.41 per share Price / Book1.96Miscellaneous Outstanding Shares36,058,000Free Float23,654,000Market Cap$523.20 million OptionableNot Optionable Beta0.60 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:SBTX) was last updated on 9/27/2024 by MarketBeat.com Staff From Our Partners10X More Profitable Than Physical Gold?The smart money is piling into gold and gold stocks. There's a backdoor gold play that could deliver 10 TIM...Monument Traders Alliance | SponsoredThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | SponsoredPrepare for an election day stock surpriseDuring his 50 years on Wall Street, legendary stockpicker Marc Chaikin traded through 13 presidential election...Chaikin Analytics | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silverback Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silverback Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.